ELCC 2022 | Limitations of genetic testing for actionable mutations in lung cancer

Jens Samol, MD, Tan Tock Seng Hospital & Faculty Appointment at Johns Hopkins University, Tan Tock Seng, Singapore, discusses the limitations of genetic testing for actionable mutations, including the accessibility and cost of testing. Testing is routinely carried out for patients with advanced-stage lung cancer, whereby the turnaround time is a critical factor. The National Comprehensive Cancer Network (NCCN) recommend using a next-generation sequencing (NGS) platform to test for actionable mutations in patients with incurable lung cancer or metastatic disease, whereby multiple mutations in various genes can be tested for simultaneously. This interview took place during the virtual European Lung Cancer Congress 2022.